Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1080

1.

Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up.

van Oppen P, van Balkom AJ, de Haan E, van Dyck R.

J Clin Psychiatry. 2005 Nov;66(11):1415-22.

PMID:
16420079
2.

Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder.

van Balkom AJ, de Haan E, van Oppen P, Spinhoven P, Hoogduin KA, van Dyck R.

J Nerv Ment Dis. 1998 Aug;186(8):492-9.

PMID:
9717867
3.

Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.

Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J.

J Clin Psychiatry. 2001 Jul;62(7):535-40.

PMID:
11488364
4.

Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.

Rufer M, Hand I, Alsleben H, Braatz A, Ortmann J, Katenkamp B, Fricke S, Peter H.

Eur Arch Psychiatry Clin Neurosci. 2005 Apr;255(2):121-8. Epub 2004 Nov 12.

PMID:
15812606
5.

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

Simpson HB, Gorfinkle KS, Liebowitz MR.

J Clin Psychiatry. 1999 Sep;60(9):584-90.

PMID:
10520976
6.

Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy.

de Haan E, van Oppen P, van Balkom AJ, Spinhoven P, Hoogduin KA, Van Dyck R.

Acta Psychiatr Scand. 1997 Nov;96(5):354-61.

PMID:
9395153
7.

Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial.

Tolin DF, Maltby N, Diefenbach GJ, Hannan SE, Worhunsky P.

J Clin Psychiatry. 2004 Jul;65(7):922-31.

PMID:
15291681
8.

Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.

Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R.

J Clin Psychiatry. 2007 Oct;68(10):1552-6.

PMID:
17960971
9.

A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder.

Saxena S, Winograd A, Dunkin JJ, Maidment K, Rosen R, Vapnik T, Tarlow G, Bystritsky A.

J Clin Psychiatry. 2001 Jan;62(1):67-72; quiz 73.

PMID:
11235937
10.

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.

McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH.

Arch Gen Psychiatry. 1994 Apr;51(4):302-8.

PMID:
8161290
11.

A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.

Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ.

J Clin Psychiatry. 2009 Jun;70(6):863-8. doi: 10.4088/JCP.08m04369. Epub 2009 May 5.

PMID:
19422759
12.

Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up.

Kordon A, Kahl KG, Broocks A, Voderholzer U, Rasche-Räuchle H, Hohagen F.

Eur Arch Psychiatry Clin Neurosci. 2005 Feb;255(1):48-50. Epub 2004 Nov 12.

PMID:
15538591
13.

Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder.

Hembree EA, Riggs DS, Kozak MJ, Franklin ME, Foa EB.

CNS Spectr. 2003 May;8(5):363-71, 381.

PMID:
12766692
14.

Treatment outcome for adolescent obsessive-compulsive disorder in a specialized hospital setting.

Björgvinsson T, Wetterneck CT, Powell DM, Chasson GS, Webb SA, Hart J, Heffelfinger S, Azzouz R, Entricht TL, Davidson JE, Stanley MA.

J Psychiatr Pract. 2008 May;14(3):137-45. doi: 10.1097/01.pra.0000320112.36648.3e.

PMID:
18520782
15.

Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study.

Catapano F, Perris F, Masella M, Rossano F, Cigliano M, Magliano L, Maj M.

J Psychiatr Res. 2006 Sep;40(6):502-10.

PMID:
16904424
16.
17.
18.

Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup.

Cottraux J, Mollard E, Bouvard M, Marks I.

Psychiatry Res. 1993 Oct;49(1):63-75.

PMID:
8140182
19.

Sudden gains in the treatment of obsessive-compulsive disorder.

Aderka IM, Anholt GE, van Balkom AJ, Smit JH, Hermesh H, van Oppen P.

Psychother Psychosom. 2012;81(1):44-51. doi: 10.1159/000329995. Epub 2011 Nov 22.

PMID:
22116471
20.

A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder.

Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV.

J Clin Psychiatry. 2006 Jul;67(7):1133-9.

PMID:
16889458
Items per page

Supplemental Content

Write to the Help Desk